Renalytix AI initiates real-world study on KidneyIntelX assay in primary care
Renalytix AI, in collaboration with Mount Sinai Hospital, is conducting a study to evaluate the KidneyIntelX assay's impact on patient management in primary care settings.
Asset / Drug
Drug and asset intelligence for Renalytix with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.